
ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-...
Agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir (CAB LA) for treatment in 133 countries Builds on the voluntary licence for CAB LA for HIV pre-exposure prophylaxis (PrEP), enabling increased …